CRL Charles River Laboratories International Inc.

$CRL Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $3.09 up 27.16% YoY • Reported revenue of $982.73M down -2.20% YoY • Charles River increased 2026 organic revenue growth guidance to at least +1.5 from 0, and non-GAAP EPS guidance to $$11.35 from $$11.15, following third-quarter outperformance led by DSA and a lower tax rate.

CHARLES RIVER $CRL Q3’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $982.7M (Est. $959M) 🟢; -2.2% YoY 🔹 Adj. EPS: $3.09 (Est. $2.97) 🟢; +27.2% YoY 🔹 Non-GAAP Oper Income: $225.8M (Est. $217M) 🟢 Raises FY26 Guide: 🔹 Reported Revenue Growth: -2.0% to -1.5% (Est. -2.5%) 🟢 🔹 Adj. EPS: $11.35-$11.55 (Est. $11.38) 🟡 🔹 Organic Revenue Growth: At least +1.5% Segment Net Revenue: 🔹 DSA: $596.3M; -0.7% YoY; +5.9% organic 🔹 Manufacturing: $178.9M; -6.2% YoY; +7.4% organic 🔹 RMS: $207.5M; -2.8% YoY; -0.6% organic Other Q3 Metrics: 🔹 Organic Revenue Growth: +4.7% 🔹 Non-GAAP Operating Margin: 23.0%; +330 bps YoY Key Updates: 🔹 Tax Reserve Reversal: $245.6M benefit; $5.06 per share Comments: 🔸 “Revenue and earnings per share outperformed our prior expectations, DSA net bookings and proposals continued to show robust, year-over-year increases”

$CRL This should have like 30,000 watchers with 100 posts a day. If there is a better stock out there in the last month or two tell me cause I sure don’t know about it. I guess if it gets to that it’ll be time to sell.

A new White House Women's Health Task Force and an NIH Women's Health Division signal incremental federal research and care funding, a mild positive for large-cap diagnostics, life-science tools and women's-health-exposed pharma. The effect is thematic and slow-moving, so calls are small and mostly indirect. $CRL $GEHC will Bullish

$CRL CRL is jumping, near 341.58, up about 8.28 percent. What stands out is the level. It's above the 333.30 high it had set earlier this month, and it was around 172 at the end of March, so this has been a huge run for a preclinical research name. The backdrop is a recovery in biotech spending. In the August report, adjusted EPS came in at 3.02 versus 2.74 expected, full year EPS guidance went up to 11.15 to 11.45, and the key discovery and safety assessment segment grew organically for the first time since 2023, with a book to bill of 1.19, its best in nearly four years. The next report is expected in early November, though I haven't seen a confirmed date. Follow me for more on the life science names.

$CRL Our read on Charles River Laboratories International, Inc. was bullish as of 11 Oct 2026, supported by the signal distribution visible in the chart attached. Trading at $301.79, the stock sits well above its 50-day moving average of $283.17 and its 200-day trend line of $212.62, backed by a positive MACD crossover and a 14-day Money Flow Index reading of 66. Fundamentals remain mixed in the short term due to a trailing net margin of -6.0% and a revenue decline of 0.7% year-on-year to $4.0 billion during the portfolio reset following the May 2026 divestitures. However, annual free cash flow reached $518.5 million in fiscal year 2025, and management raised fiscal year 2026 non-GAAP EPS guidance to $11.15-11.45. Short interest sits at 2.2 million shares, representing 4.7% of float after declining 6% month-over-month. (Disclosure: we're and this is our own research.)